Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Ratios

Catalyst Pharmaceuticals (CPRX) Gains from Sales and Divestitures (2016 - 2025)

Catalyst Pharmaceuticals filings provide 5 years of Gains from Sales and Divestitures readings, the most recent being $333865.0 for Q4 2025.

On a quarterly basis, Gains from Sales and Divestitures fell 8.5% to $333865.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $333865.0, a 8.5% decrease, with the full-year FY2025 number at $333865.0, down 8.5% from a year prior.
Gains from Sales and Divestitures hit $333865.0 in Q4 2025 for Catalyst Pharmaceuticals, down from $364861.0 in the prior quarter.
In the past five years, Gains from Sales and Divestitures ranged from a high of $364861.0 in Q4 2024 to a low of $333865.0 in Q4 2025.